Medtronic (MDT) EBITDA (2014 - 2026)

Medtronic's EBITDA history runs 13 years deep, the most recent figure standing at $1.5 billion for Q1 2026.

• In Q1 2026, EBITDA fell 11.06% year-over-year to $1.5 billion; the TTM figure through Jan 2026 stood at $6.0 billion (up 8.24% YoY), while the FY2025 annual figure was $6.0 billion, up 15.77% from the prior year.
• EBITDA came in at $1.5 billion for Q1 2026 at Medtronic, down from $1.7 billion in the prior quarter.
• In the past five years, EBITDA ranged from a high of $1.7 billion in Q4 2025 to a low of $1.1 billion in Q2 2024.
• A 5-year average of $1.4 billion and a median of $1.4 billion in 2025 frame the typical range for EBITDA.
• Across the five-year window, EBITDA plunged 32.72% in 2024 and soared 36.37% in 2025, its largest moves.
• Medtronic's EBITDA stood at $1.4 billion in 2022, then declined by 4.56% to $1.3 billion in 2023, then grew by 19.03% to $1.6 billion in 2024, then advanced by 5.71% to $1.7 billion in 2025, then decreased by 13.17% to $1.5 billion in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $1.5 billion, $1.7 billion, and $1.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison